Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS)

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of the best oversold NASDAQ stocks to buy now. On June 12, Jefferies analyst Dennis Ding maintained a bullish stance on NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), giving it a Buy rating with a $45 price target.

Ding stated that one of the primary reasons behind the optimistic rating is the company’s focus on attaining a broader FDA label through the MACE-4 endpoint for their PREVAIL study, which is anticipated to deliver notable cardiovascular benefits.

The analyst dismissed broader analyst concerns associated with stroke impacts, reasoning that the BROADWAY analysis data supports an optimistic outlook, especially with the contributions from small LDL-P and Lp(a) that coincide with expectations.

Ding further stated that another promising factor for NewAmsterdam Pharma Company N.V.’s (NASDAQ:NAMS) future performance is the potential MACE benefit from PREVAIL, which may surpass 20%. In addition, the unique position of obicetrapib in the market also paints a positive picture for NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), according to the analyst, as it may drive considerable benefits.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company that develops oral, non-statin medicine for patients at high risk of cardiovascular disease. The company’s lead product candidate is Obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that aims at preventing major adverse cardiovascular events.

While we acknowledge the potential of NAMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.